Clinical Trial

REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam

Study acronym: REVIVE
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to demonstrate safety, effectiveness and benefit-risk profile of ResQFoam for the inhospital treatment of exsanguinating, intraabdominal haemorrhage due to trauma in patients where emergent laparotomy is required.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2016-08-23; most recent amendment 2025-11-07.
Status change: Not Yet Recruiting → Recruiting 2024-07-01
Status change: Recruiting → Not Yet Recruiting 2021-10-04
Status change: Not Yet Recruiting → Recruiting 2020-11-09
Trial Details
NCT Number NCT02880163
Lead Sponsor Arsenal Medical, Inc.
Conditions Hemorrhagic Shock, Trauma, Exsanguinating Hemorrhage, Shock; Traumatic
Enrollment 40 participants
Start Date 2025-08-07
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-10